| # | Drug | Count |
|---|---|---|
| 0 | DUPILUMAB | 122 |
| 1 | ACETAMINOPHEN | 45 |
| 2 | CABOZANTINIB | 36 |
| 3 | ADALIMUMAB | 34 |
| 4 | PREDNISONE | 34 |
| 5 | CAPECITABINE | 32 |
| 6 | ALBUTEROL SULFATE | 27 |
| 7 | METHOTREXATE SODIUM | 26 |
| 8 | ACETAMINOPHEN 500MG | 25 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 25 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | COLLOIDAL SILVER | 1 | 0.0116 |
| 1 | CARBINOXAMINE MALEATE | 1 | 0.0052 |
| 2 | CHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HCL | 1 | 0.0040 |
| 3 | DELGOCITINIB | 1 | 0.0037 |
| 4 | SOFPIRONIUM BROMIDE | 1 | 0.0036 |
| 5 | SETMELANOTIDE | 1 | 0.0035 |
| 6 | ELAPEGADEMASE-LVLR | 1 | 0.0033 |
| 7 | NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE | 1 | 0.0033 |
| 8 | TOVORAFENIB | 1 | 0.0031 |
| 9 | BETAINE | 3 | 0.0029 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-4 Receptor alpha Antagonist [EPC] | 122 |
| 1 | Corticosteroid [EPC] | 78 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 61 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 54 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 40 |
| 5 | Kinase Inhibitor [EPC] | 34 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 32 |
| 7 | Anti-epileptic Agent [EPC] | 27 |
| 8 | Expectorant [EPC] | 25 |
| 9 | Benzodiazepine [EPC] | 23 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Melanocortin 4 Receptor Agonist [EPC] | 1 | 0.0035 |
| 1 | Methylating Agent [EPC] | 3 | 0.0029 |
| 2 | Medium-chain Triglyceride [EPC] | 1 | 0.0018 |
| 3 | Interferon gamma [EPC] | 2 | 0.0014 |
| 4 | Carbamoyl Phosphate Synthetase 1 Activator [EPC] | 1 | 0.0013 |
| 5 | Carnitine Analog [EPC] | 3 | 0.0008 |
| 6 | Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] | 9 | 0.0007 |
| 7 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 2 | 0.0006 |
| 8 | Pyrethroid [EPC] | 1 | 0.0006 |
| 9 | Antisense Oligonucleotide [EPC] | 5 | 0.0004 |